Off-label-brug af psykofarmaka til børn og unge i Danmark

Anne Katrine Pagsberg; Per Hove Thomsen

Off-label-brug af psykofarmaka til børn og unge i Danmark

Institut for Klinisk Medicin

2 Citationer (Scopus)

Abstract

Despite regulatory initiatives, psychopharmacological treatment of adolescents is challenged by missing trial data on efficacy and safety. In Denmark, an estimated mean off-label prescription rate of 30-40% in clinical child- and adolescent mental health services has been found in recent studies. The lowest rates were found for drugs treating ADHD (2-3%), and the highest for antipsychotics (96%) and melatonin (100%). The use of melatonin is growing, while the use of other psychopharmacological drugs appears to be stabilizing or decreasing, in spite of an increased number of adolescents treated in Danish mental health services.

Bidragets oversatte titel	Off-label prescription of psychopharmacological drugs for children and adolescents
Originalsprog	Dansk
Artikelnummer	V05170355
Tidsskrift	Ugeskrift for Læger
Vol/bind	179
Antal sider	5
ISSN	0041-5782
Status	Udgivet - 2017

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

http://ugeskriftet.dk/videnskab/label-brug-af-psykofarmaka-til-boern-og-unge-i-danmark

Citationsformater

@article{ddf332d50a1542a0ba8d48963ff21b4a,

title = "Off-label-brug af psykofarmaka til b{\o}rn og unge i Danmark",

abstract = "Despite regulatory initiatives, psychopharmacological treatment of adolescents is challenged by missing trial data on efficacy and safety. In Denmark, an estimated mean off-label prescription rate of 30-40% in clinical child- and adolescent mental health services has been found in recent studies. The lowest rates were found for drugs treating ADHD (2-3%), and the highest for antipsychotics (96%) and melatonin (100%). The use of melatonin is growing, while the use of other psychopharmacological drugs appears to be stabilizing or decreasing, in spite of an increased number of adolescents treated in Danish mental health services.",

author = "Pagsberg, {Anne Katrine} and Thomsen, {Per Hove}",

year = "2017",

language = "Dansk",

volume = "179",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Off-label-brug af psykofarmaka til børn og unge i Danmark

AU - Pagsberg, Anne Katrine

AU - Thomsen, Per Hove

PY - 2017

Y1 - 2017

N2 - Despite regulatory initiatives, psychopharmacological treatment of adolescents is challenged by missing trial data on efficacy and safety. In Denmark, an estimated mean off-label prescription rate of 30-40% in clinical child- and adolescent mental health services has been found in recent studies. The lowest rates were found for drugs treating ADHD (2-3%), and the highest for antipsychotics (96%) and melatonin (100%). The use of melatonin is growing, while the use of other psychopharmacological drugs appears to be stabilizing or decreasing, in spite of an increased number of adolescents treated in Danish mental health services.

AB - Despite regulatory initiatives, psychopharmacological treatment of adolescents is challenged by missing trial data on efficacy and safety. In Denmark, an estimated mean off-label prescription rate of 30-40% in clinical child- and adolescent mental health services has been found in recent studies. The lowest rates were found for drugs treating ADHD (2-3%), and the highest for antipsychotics (96%) and melatonin (100%). The use of melatonin is growing, while the use of other psychopharmacological drugs appears to be stabilizing or decreasing, in spite of an increased number of adolescents treated in Danish mental health services.

M3 - Tidsskriftartikel

C2 - 28874238

SN - 0041-5782

VL - 179

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V05170355

ER -

Off-label-brug af psykofarmaka til børn og unge i Danmark

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater